Clinical Trials Using CBP/beta-catenin Antagonist PRI-724
Clinical trials are research studies that involve people. The clinical trials on this list are studying CBP/beta-catenin Antagonist PRI-724. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Combination Chemotherapy and Bevacizumab with or without PRI-724 in Treating Patients with Newly Diagnosed Metastatic Colorectal Cancer
This randomized phase II trial studies how well combination chemotherapy and bevacizumab with or without CBP / beta-catenin antagonist PRI-724 (PRI-724) works in treating patients with newly diagnosed colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as leucovorin calcium, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. PRI-724 may help stop the growth of cancer cells by blocking the specific signaling pathway that cancer cells need to grow and spread. It is not yet known whether combination chemotherapy and bevacizumab works better with or without PRI-724 in treating patients with metastatic colorectal cancer.
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California